Treatment based on rising CA125 blood levels does not improve survival for recurrent ovarian cancer

Share :
Published: 3 Jul 2009
Views: 15916
Dr Gordon Rustin - Mount Vernon Cancer Center, UK
Gordon Rustin, MD, Mount Vernon Cancer Center, Hertfordshire, United Kingdom, speaking at ASCO 2009: Treatment Based on Rising CA125 Blood Levels Does Not Improve Survival for Recurrent Ovarian Cancer, Compared to Waiting for Symptoms to Arise: European researchers report that starting treatment early for an ovarian cancer relapse based on CA125 blood levels alone does not improve overall survival, compared with delaying treatment until symptoms arise.